Involvement of aberrant regulation of epigenetic mechanisms in the pathogenesis of Parkinson's disease and epigenetic-based therapies.
Parkinson's disease (PD) is known as a progressive neurodegenerative disorder associated with the reduction of dopamine-secreting neurons and the formation of Lewy bodies in the substantia nigra and basal ganglia routes. Aging, as well as environmental and genetic factors, are considered as disease risk factors that can make PD as a complex one. Epigenetics means studying heritable changes in gene expression or function, without altering the underlying DNA sequence. Multiple studies have shown the association of epigenetic variations with onset or progression of various types of diseases. DNA methylation, posttranslational modifications of histones and presence of microRNA (miRNA) are among epigenetic processes involved in regulating pathways related to the development of PD. Unlike genetic mutations, most epigenetic variations may be reversible or preventable. Therefore, the return of aberrant epigenetic events in different cells is a growing therapeutic approach to treatment or prevention. Currently, there are several methods for treating PD patients, the most important of which are drug therapies. However, detection of genes and epigenetic mechanisms involved in the disease can develop appropriate diagnosis and treatment of the disease before the onset of disabilities and resulting complications. The main purpose of this study was to review the most important epigenetic molecular mechanisms, epigenetic variations in PD, and epigenetic-based therapies.
['Renani|Pedram G|PG|', 'Taheri|Forogh|F|', 'Rostami|Daryoush|D|', 'Farahani|Najmeh|N|', 'Abdolkarimi|Hamed|H|', 'Abdollahi|Elahe|E|', 'Taghizadeh|Eskandar|E|0000-0002-7394-2539', 'Gheibi Hayat|Seyed Mohammad|SM|']
D000375:Aging D019175:DNA Methylation D044127:Epigenesis, Genetic D020022:Genetic Predisposition to Disease D006657:Histones D006801:Humans D009474:Neurons D010300:Parkinson Disease D013378:Substantia Nigra
epigenetics Parkinson's disease neurodegenerative microRNA